v3.20.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Total revenue $ 86,977 $ 101,713 $ 193,007 $ 197,290
COST OF REVENUE 58,971 52,747 118,632 101,209
Total gross profit 28,006 48,966 74,375 96,081
Operating expenses:        
General and administrative 34,613 29,577 70,957 61,719
Research and development 2,105 2,587 4,165 3,796
Sales and marketing 10,195 12,324 23,453 23,540
Total operating expenses 46,913 44,488 98,575 89,055
(Loss) income from operations (18,907) 4,478 (24,200) 7,026
Interest expense, net 1,548 1,304 2,367 3,130
Other (income) expense, net (7,405) (10) (7,628) 5,159
Loss on extinguishment of debt 1,400 1,018 1,400 1,018
Loss on termination of cash flow hedge 3,506 0 3,506 0
(Loss) income before taxes (17,956) 2,166 (23,845) (2,281)
Income tax (benefit) expense (11,132) 175 (10,043) (1,848)
Net (loss) income $ (6,824) $ 1,991 $ (13,802) $ (433)
NET (LOSS) INCOME PER SHARE        
Basic (in dollars per share) $ (0.06) $ 0.02 $ (0.13) $ (0.00)
Diluted (in dollars per share) $ (0.06) $ 0.02 $ (0.13) $ (0.00)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING        
Basic (in shares) 107,887 98,297 106,209 96,734
Diluted (in shares) 107,887 102,336 106,209 96,734
Clinical Services        
Total revenue $ 73,884 $ 88,982 $ 166,866 $ 175,192
Total gross profit 25,127 42,602 69,186 86,161
Pharma Services        
Total revenue 13,093 12,731 26,141 22,098
Total gross profit $ 2,879 $ 6,364 $ 5,189 $ 9,920

Source